摘要
目的观察茶碱缓释片联合沙美特罗/氟替卡松吸入剂(SFC)治疗哮喘的临床疗效。方法将哮喘急性加重患者随机分为两组,治疗组口服茶碱缓释片200mg,bid;吸入SFC50/250μg,bid;对照组吸入SFC50/250μg,bid。均治疗24周,记录治疗期间至少1次以上急性加重病例数、治疗结束时完全控制病例数和治疗前后患者肺功能。结果治疗组和对照组分别有135和130例完成治疗。治疗组和对照组治疗期间出现至少1次以上急性加重分别为40例和61例,差异有统计学意义(P<0.01);治疗组和对照组治疗后最大中期呼气流量(FEF25%-75%)占预计值比例分别为(66.9±18.8)%和(57.4±17.6)%,差异有统计学意义(P<0.01)。结论茶碱缓释片联合SFC能更好地控制哮喘急性加重,改善小气道功能。
Objective To compare the efficacy of theophylline combined with salmeterol/fluticasone propionate combination product( SFC) with SFC in asthmatic patients. Methods In this study,314 patients were randomly divided into control group and treatment group.In the treatment group,patients received 200 mg theophylline and 50/250 μg SFC twice a day for 24 weeks.And patients in control group received 50/250 μg SFC twice a day for 24 weeks.The outcomes were evaluated by the level of asthma control( assessed by the Asthma Control Test),the number of patients experiencing exacerbation more than once during the 24-week treatment period and lung function tests performed before and after treatment. Results A total of 265 patients completed the trial( 135 of the treatment and 130 of control group).There were significantly fewer patients whose asthma exacerbation occurred more than once in the theophylline plus SFC group when compared with the SFC group( 29.6%vs.46.9%,P<0. 01). Theophylline combined with SFC improved the forced expiratory flow( FEF) from 25% to 75% of vital capacity( FEF25%-75%) value,from( 57.4±17.6)% to( 66.9±18.8)%,which indicates enhanced small airway function significantly( P<0.01). Conclusion The combination of theophylline and SFC may protect against asthma exacerbations,and improve small airway function.
作者
余红缨
叶玲
聂汉祥
YU Hongying;YE Ling;NIE Hanxiang(Department of Respiratory Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China)
出处
《医药导报》
CAS
北大核心
2019年第7期914-916,共3页
Herald of Medicine
关键词
茶碱缓释片
沙美特罗/氟替卡松吸入剂
哮喘
小气道功能
Theophylline
Salmeterol/fluticasone propionate combination product
Asthma
Small airway function
